Overview of Severin NF

Quick Facts

Property	Description
Active ingredient	Nimesulide
Form	Oral tablets, capsules, granules, topical gels, and suppositories
Pharmacological class	Nonsteroidal Anti-inflammatory Drug (NSAID)
Common purpose	Relief of acute pain, inflammation, and fever
Origin	Synthetic, Sulfonanilide derivative

What Type of Medicine is Severin NF?

Severin NF is a pharmaceutical product whose active substance is Nimesulide. It is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID), a group of medicines clinically recognized for their ability to modulate pain and inflammation. Chemically, Nimesulide is a distinct synthetic sulfonanilide derivative, a structure that differentiates it from older NSAIDs. Functionally, it is identified as a preferential cyclooxygenase-2 (COX-2) inhibitor.

Composition, Origin, and Available Forms

The medicine is a single-component product focused entirely on the actions of Nimesulide (C13H12N2O5S), manufactured via a synthetic process. Nimesulide is prepared in multiple ways, a factor that contributes to its flexibility in application. These forms include those for systemic use, such as oral tablets, capsules, and granules for suspension, and forms for localized application, such as topical gels or rectal suppositories. The variety of forms ensures flexibility in its route of administration (oral, topical, or rectal), allowing management of acute pain episodes in adult patients.

General Benefit and Core Function

The core function of Severin NF is to provide relief through a combination of actions: it is anti-inflammatory, analgesic (pain-relieving), and antipyretic (fever-reducing). This therapeutic profile is intended to dampen the physical symptoms that arise from acute inflammatory conditions. For instance, in a typical use scenario such as musculo-skeletal discomfort, the general benefit is the effective management and reduction of the intensity of pain and swelling.

What side effects are possible with Severin NF?

Possible Side Effects and Safety Information

Official regulatory documents classify the safety profile of Severin NF (Nimesulide) by listing possible adverse reactions according to frequency and the affected System-Organ Class (SOC).

Adverse Reaction Classifications

Adverse effects are documented across several physiological systems. The most frequent events are generally gastrointestinal disorders (e.g., diarrhea, nausea, and vomiting), classified as Common in regulatory contexts.

System-Organ Class	Examples of Documented Effects
Hepatobiliary Disorders	Liver enzyme elevations, hepatitis, acute liver failure
Gastrointestinal Disorders	Ulceration, bleeding, and perforation
Skin and Subcutaneous Tissue	Rash, itching, and very rare severe reactions (e.g., Stevens-Johnson Syndrome)
Vascular/Cardiac Disorders	Hypertension, and increased risk of arterial thrombotic events (myocardial infarction, stroke)

Serious Safety Considerations

The most significant documented risks involve the hepatobiliary and gastrointestinal systems. Serious adverse reactions include acute liver injury (including fatal cases and those requiring transplantation), and potentially fatal gastrointestinal haemorrhage and perforation. These risks are relevant even following short courses of therapy, with severe skin reactions often manifesting early in treatment.

Safety Constraints and Special Populations

Nimesulide is associated with official safety constraints. Use is contraindicated in patients with severe hepatic or renal impairment. The drug is generally restricted to second-line treatment for approved indications in some regions. Older adults (the elderly) are noted in regulatory information to be particularly susceptible to NSAID-related adverse effects, specifically severe gastrointestinal and renal complications. The medicine may also impair female fertility.

Overdose and Emergency Response

Documented Overdose Manifestations and Severe Outcomes

Regulatory documents indicate that Nimesulide overdose may initially present with common signs, including gastrointestinal disturbances such as nausea, vomiting, and epigastric pain, alongside Central Nervous System effects like drowsiness and lethargy. However, the official profile emphasizes the potential for severe, life-threatening outcomes. These complications include acute liver injury, which may progress to fulminant hepatic failure, acute renal failure, and critical gastrointestinal complications such as bleeding and perforation. Extreme cases are officially documented to involve convulsions and shock. Regulatory warnings also indicate that elderly patients are at an increased risk for these more severe outcomes, making this a specific consideration in overdose scenarios.

When to Seek Immediate Medical Help and Official Management

Due to the potential for severe, delayed toxicity, regulatory authorities mandate that immediate medical attention must be sought for any suspected overdose. Contacting emergency services or a poison control center is required immediately, and urgent medical care is mandatory if severe manifestations such as seizures, gastrointestinal bleeding, or signs of hepatic failure are observed. The official prescribing information confirms that no specific antidote is known for acute Nimesulide toxicity. Consequently, management is strictly symptomatic and supportive. In a clinical setting, procedures such as the administration of activated charcoal may be considered to reduce absorption, and patients require mandatory monitoring of liver and renal function.

Therapeutic Uses of Severin NF

Severin NF: Main Uses and Therapeutic Benefits

Severin NF is a medicinal product used to provide symptomatic treatment for a range of conditions. Its primary function is the relief of pain and the management of fever and inflammation.

Quick Facts: Therapeutic Domain

Relief of pain
Management of fever
Reduction of inflammation

The main uses of Severin NF include the management of acute pain and the symptomatic treatment of osteoarthritis (degenerative joint disease). It is also used to address painful menstrual periods (primary dysmenorrhea). By targeting processes linked to inflammation, it can contribute to pain reduction in these areas. The use of the active substance in Severin NF, nimesulide, is subject to specific regulatory guidelines due to potential liver safety concerns and is therefore restricted in duration and indication in some regions.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Severin NF — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label):

Adults (18 years and older) and Adolescents (from 12 to 18 years).
Patients with mild to moderate renal impairment.

Populations for whom use is not recommended (if applicable):

Women attempting to conceive.

Populations for whom use is contraindicated:

Children under 12 years.
Any degree of Hepatic Impairment or Active Liver Disease.
Severe Renal Impairment or Severe Heart Failure.
Active or History of Recurrent Gastrointestinal Ulceration or Bleeding.
Third Trimester of Pregnancy and Breastfeeding.
Severe Coagulation Disorders or Known Hypersensitivity to Nimesulide or other NSAIDs.

Age-related eligibility rules:

Contraindicated under 12 years. Elderly patients are permitted but require appropriate clinical monitoring.

Eligibility-related restrictions:

Use is restricted to second-line treatment, meaning it is only prescribed after other initial treatment options have failed.

Eligibility Classifications (High-Level)

Eligibility severity classification (as defined in official documents): Contraindicated, Not Recommended, and Requires Caution/Monitoring.

Regulatory basis (EMA / FDA / etc.): EMA (European Medicines Agency) Summary of Product Characteristics and national health authority mandates.

Resulting Eligibility Structure

Severin NF is contraindicated in children under 12 years of age and throughout the third trimester of pregnancy.
The medicine is contraindicated in patients with any degree of hepatic impairment, severe renal impairment, or severe heart failure.
Use is permitted in adults and adolescents over 12 years, but is officially restricted to a second-line treatment capacity.

Connection to the overall eligibility profile (2–4 sentences): Official regulatory documents define the eligibility profile by establishing a high barrier for use due to potential safety concerns, especially regarding liver function. The medicine is absolutely contraindicated in vulnerable groups, including those with severe organ compromise and the pediatric population under 12 years. For eligible adults, use is constrained to a second-line role to minimize population-level risk exposure.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Severin NF (Nimesulide) is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

Pharmacokinetic and Metabolic Interactions

Severin NF is a documented inhibitor of the CYP2C9 enzyme. Co-administration with drugs that are substrates of CYP2C9 may result in increased plasma concentrations of the co-administered drug. Clinically, this interaction structure impacts substances such as Lithium, whose clearance may be reduced, potentially leading to elevated plasma levels.

Pharmacodynamic Interactions and Restrictions

Co-administration with other substances is subject to specific restrictions due to the risk of additive toxicity. The label classifies several combinations as non-recommended or prohibited:

Contraindicated Combinations: Co-administration with other Non-Steroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 inhibitors, and Acetylsalicylic acid at anti-inflammatory doses is restricted. Exposure to potentially hepatotoxic substances, including excess alcohol, is prohibited due to the risk of additive hepatic reactions.
Bleeding Risk: Co-administration with Anticoagulants (e.g., Warfarin), Oral Corticosteroids, Anti-platelet agents, and SSRIs may result in an increased risk of gastrointestinal bleeding.
Antihypertensive and Diuretic Agents: The co-administration with Diuretics (e.g., Furosemide) and certain Antihypertensives (ACE inhibitors, Angiotensin II Antagonists) can reduce the efficacy of these agents and potentially lead to the deterioration of renal function.

Timing and Population Cautions

Official labeling requires caution regarding the use of Severin NF less than 24 hours before or after treatment with Methotrexate. The clinical relevance of all documented interactions is heightened in elderly patients and those with reduced renal function.

Mechanism of Action

How Severin NF Works

Severin NF (Nimesulide) acts through a distinct, multi-level pharmacodynamic mechanism to modulate the signaling dynamics involved in the peripheral inflammatory response and central thermoregulation.

Targeted Inhibition of the Inflammatory Cascade

The primary mechanism involves the preferential inhibition of the Cyclooxygenase-2 ( COX-2) enzyme, which is responsible for synthesizing Prostaglandin E2 at the site of tissue injury. By reducing the generation of this key mediator, the drug directly inhibits the generation of PGE2, a key mediator in peripheral nociceptor sensitization and hypothalamic thermoregulation. This results in the physiological modulation of nociceptive input and the lowering of the thermoregulatory set point.

️ Non-COX Modulation and Anti-Catabolic Action

The drug's unique mechanism extends beyond the COX pathway, engaging in important non-COX modulation. This includes acting as an antioxidant by scavenging Reactive Oxygen Species (ROS) and inhibiting other pro-inflammatory enzymes like Phosphodiesterases (PDEs) and Matrix Metalloproteinases (MMPs). These secondary actions modulate the functional activation of inflammatory cells and reduce MMP-mediated degradation of extracellular matrix components, which contributes to the regulation of localized fluid accumulation and the maintenance of structural integrity.

Dosage and Administration Information

Administration Guidelines for Nimesulide

Note: The following guidelines describe the standard application of the active ingredient, Nimesulide.

Instruction Category	Rule
Route of Administration	Oral
Dosing Schedule	100 mg twice daily (bid)
Timing in Relation to Meals	Must be taken after a meal
Maximum Duration of Use	The treatment course must not exceed 15 days
Age-Group Rules	Contraindicated in children under 12 years of age

Procedural Structure

The instructions establish a precise protocol for administering the medicine:

Selection Context: The decision to prescribe the medicine is based on an assessment of individual risks, as it is restricted to second-line use.
Dose Intake: Take a 100 mg dose of the medicine.
Timing: Ensure the administration is completed after a meal.
Frequency: The second 100 mg dose is taken approximately 12 hours later, not exceeding the total daily dose of 200 mg.
Course Limit: The medicine must be discontinued if the total duration of use reaches 15 days, regardless of the patient's status.

These guidelines define the minimum effective dose for the shortest duration necessary, the precise timing of administration, and include a 15-day limit on the course of treatment. This structure ensures that the medicine is used in a standardized manner.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Severin NF

Evidence for use in Acute Pain

The research supporting the study of Severin NF (Nimesulide) for acute pain is primarily based on short-term Randomized Controlled Trials (RCTs) and meta-analyses. These research efforts explored the profile of measured outcomes related to physical discomfort in conditions such as musculoskeletal injuries and post-operative discomfort in adults. The trials explored outcomes related to physical discomfort by measuring changes in pain intensity over short, defined time intervals.

Studies monitored how patient-reported outcomes describing perceived discomfort evolved in the observed populations compared to both inactive placebos and other active treatments. Research reports document specific timeframes for the reported onset of change in physical discomfort across different patient populations. Findings consistently described comparative measurements against active treatments for short-term symptom patterns.

Evidence for use in Primary Dysmenorrhoea

The clinical evidence base for Severin NF in the context of primary dysmenorrhoea (painful menstrual periods) has been built through comparative randomized controlled trials and subsequent regulatory assessments. These studies were applied in research contexts relevant in trials assessing episodic symptom patterns during the menstrual cycle. The trials monitored outcomes capturing phases of heightened symptom activity, such as the level of abdominal pain and associated systemic discomfort.

Research describes patterns related to outcomes of physical discomfort during the treatment cycle when the medicine was evaluated. These studies focusing on episodes where symptoms become more noticeable reported patterns of symptomatic change compared to control groups. Studies monitored findings related to active comparator treatments.

Evidence for Symptomatic Treatment of Osteoarthritis Flare-ups

Research for this use primarily involves historical multicenter double-blind studies and comparative trials. Severin NF was evaluated in adult and older adult patients with painful osteoarthritis, a condition marked by functional limitations and cycles of stability and flare-ups. The research examined outcomes reflecting daily functioning or activity level, specifically monitoring changes in pain on movement and objective functional capacity scores.

Because osteoarthritis is a chronic condition, the evidence is limited to supporting only short-term symptomatic relief during a flare-up, and research reflects only short-term treatment durations of up to 15 days. Although longer trials were observed in some studies, the long-term effects are not fully established or supported by current regulatory guidance, and insufficient data remain for chronic management of this condition.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Severin NF (FAQ)

Q: How quickly does Severin NF start to work?

Official product information indicates that Nimesulide has a rapid onset of action. Research documentation states that a measurable change in pain and inflammation is observed, with reported onset times often occurring within 15 minutes of drug intake.

Q: What happens if I forget to take a dose of Severin NF?

Patient leaflets describe a procedure where, if a dose is missed, taking it upon remembering is often the course. However, if the time is near for the next scheduled dose, the prescribed instruction is to skip the missed dose and return to the regular schedule. Regulatory guidance specifies that a double dose should not be taken to make up for a missed dose.

Q: Is it normal to feel a little dizzy after starting Severin NF?

Dizziness is a documented possible side effect listed in official regulatory safety profiles for this medicine, although it is typically reported as infrequent. Official patient leaflets suggest caution for individuals experiencing this effect.

Q: Why do people sometimes say they have trouble sleeping on Severin NF?

Official product documentation does not typically list trouble sleeping (insomnia) as a common side effect. However, the regulatory safety profile does note that other effects related to the central nervous system may occasionally be experienced.

Q: Is Severin NF a controlled substance?

Severin NF’s active ingredient, Nimesulide, is classified as a Nonsteroidal Anti-inflammatory Drug (NSAID). According to government classifications, this class of drugs is generally not scheduled as controlled substances in regions where the product is available for systemic use.

Q: Does taking Severin NF require any special blood tests?

Official regulatory information advises that appropriate clinical monitoring is recommended due to potential risks to the liver and kidneys. This attention to monitoring is particularly emphasized for older adults and individuals with pre-existing reduced organ function.

Q: What should I do if I think I'm having a rare side effect from Severin NF?

The official guidance is that suspected adverse drug reactions are reported according to the national drug monitoring authority’s system. These established systems are in place to track the safety profile of the medicine.

Q: Can Severin NF cause weight gain or weight loss?

While weight changes are not listed as common side effects in the official safety profile, regulatory post-marketing data has documented occurrences of oedema. Oedema is the medical term for fluid retention or swelling.

Q: Does Severin NF interact with birth control pills?

Official regulatory information advises caution regarding the use of Nimesulide with other drugs that may affect the liver. Official information recommends caution in these cases involving certain types of hormonal contraception.

Q: Does Severin NF make you feel tired or drowsy?

Somnolence, which is the medical term for drowsiness, is listed as a documented side effect in the official product information. This effect is generally reported as infrequent for patients taking the medicine.

Q: Has Severin NF been studied in people with diabetes?

Regulatory documents do note that Nimesulide may interact with certain products prescribed to lower blood sugar (hypoglycemic products). This reference indicates that the drug’s use may be relevant to individuals with diabetes.

Q: How long does Severin NF stay in your system after the last dose?

Pharmacokinetic data in the official documents describes the time the drug takes to be eliminated from the body, known as the elimination half-life. The half-life for Nimesulide typically ranges from approximately 1.8 to 4.7 hours.

Q: What is the risk of dependence or addiction with Severin NF?

Severin NF belongs to the class of medicines known as Nonsteroidal Anti-inflammatory Drugs (NSAIDs). According to official classifications, this class of drugs is not associated with a risk of dependence or addiction.

Q: Are there special warnings about sunlight exposure while on Severin NF?

Official patient guidance, particularly concerning topical forms of the active substance, includes warnings about excessive exposure to direct sunlight or sunbeds. This is due to the potential for the medicine to increase the skin's sensitivity to light, known as photosensitivity.

Q: Does Severin NF affect mood or energy levels?

The drug's primary function is pain and inflammation relief, but official safety information documents central nervous system effects. While changes in general mood or energy levels are not commonly reported, these effects are part of the broader safety profile.

Q: Why is it important to take Severin NF every day?

The official regulatory schedule for this medicine mandates twice-daily dosing. This frequent administration is designed to help maintain consistent levels of the active substance in the body, which is necessary for the medicine’s intended use.

Q: What are the rules regarding driving or operating heavy machinery while taking Severin NF?

Official product information advises that the ability to drive or use heavy machinery may be impaired by certain side effects. The official information indicates that individuals experiencing effects such as dizziness, vertigo, or drowsiness should refrain from operating vehicles or machinery.

Q: Can taking too much Severin NF cause serious problems?

Regulatory documents detail the signs of taking more than the prescribed amount. Reported symptoms can include stomach pain, nausea, and lethargy. More severe effects, such as acute renal failure or gastrointestinal bleeding, are documented in official safety information as potentially occurring in rare cases.

Q: Does Severin NF cause anxiety?

While anxiety is not listed as a common side effect, the official safety document includes nervous system and psychiatric disorders as part of its documented safety profile.

How should Severin NF be stored and disposed of?

How to Store and Dispose of Severin NF

The storage and disposal requirements for Severin NF (Nimesulide) are officially defined to ensure stability and environmental safety.

Storage Requirements

Condition	Regulatory Requirement
Environmental Protection	Must be stored in a well-ventilated place and kept away from heat and direct sunlight to protect the integrity of the product.
Container Integrity	The container must be kept tightly closed and stored in original containers.
Child Safety	The medicine must be kept strictly away from the reach of children and pets.

Disposal Instructions

Unused or expired product must not be released to the environment. Official guidelines require that the contents and container be disposed of at an approved waste disposal plant in accordance with local and national regulations. The product should not be placed in household trash or flushed down a toilet or drain.

Severin NF